Management of Ant Bite Reactions

Local (Simple) Reactions

Symptomatic care with cold compresses and oral antihistamines is sufficient for uncomplicated ant‑bite skin reactions; systemic involvement mandates immediate intramuscular epinephrine and transport to an emergency department. 1
The majority of ant stings produce a transient, self‑limited local reaction characterized by redness, swelling, itching, and pain at the bite site, typically resolving within hours to a few days without specific therapy. 2
Fire‑ant stings uniquely generate a sterile pseudopustule (a necrotic vesicle) within 24 h that is pathognomonic and should be left intact and kept clean to avoid secondary infection. 1, 3

Large local reactions are defined by swelling > 10 cm that spreads contiguously from the sting site, enlarges over 24–48 h, and usually resolves in 5–10 days. 2, 4
Management includes:
Antibiotics are not indicated for large local reactions because the swelling is driven by allergic inflammation rather than infection; secondary bacterial infection is uncommon even after fire‑ant stings. 1, 5, 2

Systemic manifestations may include cutaneous urticaria/angioedema, bronchospasm, upper‑airway obstruction (laryngeal or tongue edema), hypotension/shock, cardiac arrhythmias or coronary spasm, and gastrointestinal symptoms (nausea, vomiting, diarrhea). 2, 6
Immediate emergency treatment:
Delayed epinephrine administration is associated with fatal outcomes; there are no absolute contraindications to epinephrine even in patients with pre‑existing cardiovascular disease, and antihistamines or corticosteroids should not replace epinephrine. 1, 5, 6

For reactions limited to the skin (cutaneous‑only systemic reactions), initial therapy may consist of antihistamines and close observation, but epinephrine must be readily available. 1, 5
If a stinger remains attached, it should be removed within 10–20 seconds by flicking or scraping with a fingernail; grasping the venom sac should be avoided because it can inject additional venom. 3, 6

Patients who experienced systemic reactions should receive:
Risk stratification: individuals with a prior systemic reaction have a 25 %–70 % chance of a future systemic reaction, depending on the severity of the initial event; venom immunotherapy (VIT) can nearly eliminate this risk when indicated. 1, 9, 3

VIT is recommended for all patients with documented systemic reactions and confirmed venom‑specific IgE sensitization. 4
Exception: children ≤ 16 years old who have only cutaneous systemic reactions generally do not require VIT, as their risk of a future systemic reaction is ≈ 10 %. 10
The recommendation for VIT is based on expert consensus; high‑quality controlled trial data are limited. 5, 4